Fosun Pharmaceutical (600196) Stock Price, Fundamentals & Analysis

What 600196 does

Fosun Pharmaceutical (600196) is a stock listed on the Shanghai Stock Exchange in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Headquartered in Shanghai, China, the company operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. Its pharmaceutical manufacturing covers therapeutic areas such as solid oncology, immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also produces mRNA vaccines, medical aesthetic devices, mechanical ventilation devices under the Breas brand, mobile pre-hospital care, professional in-hospital surgery and medical devices, and high-end surgical robots and medical consumables.

Key numbers explained

• The current price is 22.84 CNY, which is the last traded price in the market.
• The trailing P/E ratio of 17.8 divides the current share price by the last twelve months of earnings per share (1.28 CNY), showing how much investors pay per unit of recent earnings.
• The forward P/E ratio of 20.8 uses expected future earnings instead of past earnings, reflecting market views on growth.
• The dividend yield of 1.71% tells you the annual dividend as a percentage of the current share price; the ex-dividend date is Jul 27, 2026, and 25% of earnings are paid out as dividends.
• The beta of 0.43 suggests the stock has historically moved less than the overall market, indicating lower volatility.
• The 52-week range is 20.85 – 30.09 CNY, and the price change over the last 52 weeks is -22.2%, showing the year-over-year performance.
• The debt-to-equity ratio of 61.7% compares total debt to shareholders' equity, indicating the company's financial leverage.
• The price-to-book ratio of 1.24 compares the market price to the book value per share.

What to watch

Fosun Pharmaceutical (600196) is part of the Shanghai Stock Exchange and can be compared with peers such as Zhangzhou Pientzehuang Pharmaceutical (600436), Shanghai Pharmaceuticals Holding (601607), and WuXi AppTec (603259). Investors often monitor revenue growth, which stands at 2.7% year over year, alongside profit margins and operating margins to gauge business efficiency. The company's exposure to the healthcare sector and its product mix across pharmaceuticals, devices, and services can make it sensitive to regulatory changes, drug approval cycles, and broader health policy shifts. As a component of the CSI 300 index, its movements may also reflect broader Chinese large-cap trends.